Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Treasury Shares (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Treasury Shares for 10 consecutive years, with $82129.0 as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares changed N/A to $82129.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $82129.0, a N/A change, with the full-year FY2025 number at $82129.0, changed N/A from a year prior.
  • Treasury Shares was $82129.0 for Q4 2025 at Crescent Biopharma, down from $438386.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $590654.0 in Q2 2021 to a low of $48133.0 in Q3 2024.
  • A 5-year average of $225915.1 and a median of $163243.0 in 2022 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: crashed 63.43% in 2022, then skyrocketed 810.78% in 2025.
  • Crescent Biopharma's Treasury Shares stood at $345600.0 in 2021, then tumbled by 40.75% to $204785.0 in 2022, then crashed by 42.79% to $117157.0 in 2023, then tumbled by 58.92% to $48133.0 in 2024, then surged by 70.63% to $82129.0 in 2025.
  • Per Business Quant, the three most recent readings for CBIO's Treasury Shares are $82129.0 (Q4 2025), $438386.0 (Q3 2025), and $118864.0 (Q2 2025).